rticularly high in key International markets and especially in China thanks to a strong launch trajectory.

Galderma also made progress in preparing the next frontier of growth in Injectable Aesthetics, maintaining its commercial and regulatory momentum.

In Neuromodulators, Relfydess is quickly ramping up and is now approved in 23 International markets. On February 2, 2026, Galderma announced that the U.S. Food & Drug Administration (FDA) accepted the resubmission of Relfydess’ Biologics License Application (BLA) for the temporary improvement of moderatetosevere glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults.

In Fillers, the U.S. FDA approved Restylane Lyft™ with Lidocaine in November 2025 for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion. In Biostimulators, Galderma continues to demonstrate leadership in regenerative aest
=*=*=*=*=*=
当前为第9/55页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页